Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: A meta-analysis
Open Access
- 1 January 2013
- journal article
- research article
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 45 (1), 54-60
- https://doi.org/10.4103/0253-7613.106436
Abstract
Objectives: Terlipressin improves renal function in hepatorenal syndrome (HRS) is a known fact. However the reason for lack of its long-term survival benefits despite improvement in renal function remains unclear. The aim of this study was to analyze the survival benefits of terlipressin in HRS and to address the issue of non-responder state to terlipressin.Materials and Methods: Electronic databases and relevant articles were searched for all types of studies related to HRS and use of terlipressin in HRS. Reduction in all-cause mortality rate was the primary outcome measure. Reduction in mortality rate due to HRS and other causes of death were also analyzed. Results: With total 377 patients analyzed from eight eligible studies; terlipressin reduced all-cause mortality rate by 15% (Risk Difference: -0.15%, 95% CI:-0.26 to -0.03). Reduction in the mortality rate due to HRS at three months was 9% (Risk Difference:-0.09%, 95% CI:-0.18 to 0.00). Conclusion: Terlipressin has long term survival benefits perhaps at least up to three months but only with HRS as a cause of death not for other causes of death. Benefits and role of antioxidants like N- Acetylcysteine (NAC) in non-responder patients' needs to be studied further. Long-term use of low dose terlipressin (<4mg/d) plus albumin and addition of antioxidant NAC to this regimen may help in improving both HRS reversal rate and survival rate in non-responders to terlipressin.Keywords
This publication has 26 references indexed in Scilit:
- Hepatorenal Syndrome: Are We Missing Some Prognostic Factors?Digestive Diseases and Sciences, 2011
- Terlipressin and Albumin vs Albumin in Patients With Cirrhosis and Hepatorenal Syndrome: A Randomized StudyGastroenterology, 2008
- A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal SyndromeGastroenterology, 2008
- Pathogenesis and Treatment of Hepatorenal SyndromeSeminars in Liver Disease, 2008
- Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndromeHepatology, 2007
- Vitamin E supplementation reverses renal altered vascular reactivity in chronic bile duct-ligated ratsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2007
- Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trialsAlimentary Pharmacology & Therapeutics, 2007
- Hepatorenal SyndromeClinical Journal of the American Society of Nephrology, 2006
- Vitamin E prevents renal dysfunction induced by experimental chronic bile duct ligationKidney International, 2003
- Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndromeJournal of Hepatology, 1998